New Fluids for Peritoneal Dialysis : why do we need them and what is it about?

Abstract

Peritoneal dialysis (PD) fluids generate concentration and osmotic gradients across the peritoneal membrane to remove uremic toxins and to achieve ultrafiltration. The use of current-era dialysis fluids also drives peritoneal and systemic pro-inflammatory, pro-fibrotic and pro-angiogenic processes that could be linked to patient outcomes. As the most frequent causes of PD technique failure are mortality, infections, insufficient solute clearance and ultrafiltration failure, it is important to reflect on the effects and modifiable power of the PD fluids’ compositions.

This paper discusses the peritoneal and systemic effects of glucose-based PD fluids and the evidence on the use of icodextrin and amino-acid based alternatives. Recent innovations in PD fluids try to overcome the peritoneal and systemic toxicities of current formulations by using an alternative osmotic agent and/or by counteracting the metabolic effects of the carbohydrate load by the PD fluid.

Introduction

Peritoneal dialysis (PD) fluids generate a concentration gradient across the peritoneal membrane allowing diffusion of uremic toxins from the patient’s circulation towards the peritoneal cavity. Diffusion is a bi-directional process, hence, small molecules within the PD fluid will also be absorbed by the patient during a PD dwell. The osmotic gradient exerted by the PD fluid on the other hand allows water flux across the peritoneal membrane. The application of the physical principles of diffusion and osmosis by a PD fluid dwelling in the peritoneal cavity allows to manage clearance and volume status of the patient during PD.

PD offers similar overall survival compared to center-hemodialysis with a trend towards a survival advantage for patients treated with PD in the first years after dialysis start [1][2]. Nevertheless, overall patient survival remains poor with survival probability of only 47% at 5 years after dialysis initiation [1]. Among patients surviving, PD technique failure is not uncommon with 1- and 2-year death-censored PD technique failure rates of 23% and 35% respectively in a contemporary European cohort [3]. Common causes of death-censored PD technique failure over time are infections, insufficient clearance and/or ultrafiltration problems [3].

This article describes the composition of PD fluids and their peritoneal and systemic effects. Although the primary goal of PD fluids is to serve solute removal and ultrafiltration, dialysis fluids also play a role in peritoneal membrane integrity, and systemic absorption of PD fluids influence systemic metabolic pathways. We discuss how novel developments in PD fluids overcome the downsides of current-era PD fluids and how PD fluids innovations aim to optimize the composite outcome of solute clearance, ultrafiltration, peritoneal membrane changes over time on PD and systemic effects by the PD fluid (Figure 1).

Figure 1.Peritoneal dialysis fluids serve solute removal and ultrafiltration. PD fluids also affect peritoneal membrane integrity and systemic absorption of PD fuids solutes influence systemic metabolic pathways. PD fluids innovations aim to optimize the composite outcome of solute clearance, ultrafiltration, peritoneal membrane changes over time on PD and systemic effects by the PD fluid.

First-generation peritoneal dialysis fluids

First-generation PD fluids, also called conventional PD fluids, contain electrolytes, a buffer, and glucose as the primary osmotic agent (Table I). The glucose content of these solutions is 10-50 times higher than the plasma glucose concentration. The heat sterilization process of the PD fluids leads to the production of glucose degradation products (GDPs), despite being performed at low pH. Conventional PD fluids are thus characterized by low a pH, a high glucose and a high GDP content.

A landmark study published in 2002 showed significant histopathologic damage of the peritoneal membrane over time with the use of these conventional PD fluids. After prolonged exposure to low pH, high glucose and high GDP fluids, follow-up histopathological assessments of the patients’ peritoneal membrane demonstrated mesothelial cell loss, submesothelial thickening, angiogenesis, and peritoneal vasculopathy [4]. In the early 2000’s, it was also recognized that peritoneal solute transport increases with time on treatment in a proportion of patients treated with PD and that this increase was associated to a higher peritoneal exposure to hypertonic glucose [5]. Although change in solute transport status over time is associated to glucose exposure, the functional and histopathological changes within the peritoneal membrane induced using low pH, high glucose and high GDP PD fluids guided the “biocompatibility hypothesis of PD fluids”. The hypothesis of biocompatibility suggests that morphological and functional peritoneal damage might be caused by conventional PD fluids - low pH, high glucose and high GDPs content PD fluids - and that these changes might be attenuated by second generation, so called biocompatible fluids.

Second-generation peritoneal dialysis fluids

To decrease the toxicity of low-pH, high glucose and high GDP PD fluids on the peritoneal membrane, multi-chambered bags were developed allowing glucose to be sterilized separately at very low pH, generating less GDPs. Before use, the glucose compartment is mixed with the other compartment(s) of the PD fluid containing electrolytes and a buffer. After mixing the different chambers of the PD fluid bag, a neutral pH PD fluid is obtained containing less GDPs compared to the first-generation PD fluids. Second-generation PD fluids are thus defined by their neutral pH and lower GDP content and are so-called biocompatible solutions (Table I).

Table I.Composition of currently commercially available PD fluids.

	Plasma reference (adult)	First-generation G%-based fluid	Second-generation G%-based fluid	Amino-acid solution	Icodextrin
		"Low pH, high GDP solutions"	”Neutral pH, low GDP solutions"
Electrolytes (mmol/L)
Sodium	136-145	132	132-134	132	133
Calcium	1.12-1.32	1.25/1.75	1.25-1.75	1.25	1.75
Magnesium	0.65-1.05	0.25/0.75	0.25/0.5	0.25	0.25
Chloride	98-107	95/102	95-104	105	96
Potassium	3.5-5.1	0	0	0	0
Buffer (mmol/L)
Acetate	0
Lactate	0.5-2	40/35	10-15/35/0	40	40
Bicarbonate	22-28		25/0/34
pH	7.4	5.5	7.0-7.4	6.7	5.5
Osmotic agent (g/dL) (osmolality)
Glucose	0.05 - 0.1	1.36/2.27/3.86	1.36-1.5/2.27-2.5/3.86-4.25
	280-300	347/398/486	± 350/397/490
Amino acid	0.05 - 0.1			1.1
	280-300			365
Icodextrin					7.5
					284

Preclinical in vitro and in vivo studies using second-generation PD fluids showed promising histopathological effects with reduced mesothelial damage induced by the biocompatible fluid, less epithelial-to-mesenchymal transition (EMT), less deposition of GDPs, decreased sub-mesothelial fibrosis and angiogenesis and less progression of vasculopathy with better preservation of the endothelial glycocalyx [6][7][8][9]. Also, observational data from clinical practice in Japan suggest that biocompatible PD fluid use contributes to decreased encapsulated peritoneal sclerosis development, the ultimate stage of histopathological changes of the peritoneal membrane [10][11]. However, evidence of clinical benefits is still debated. Results of randomized controlled clinical trials and meta-analyses comparing the effects of biocompatible versus conventional PD fluids are less clear. Overall, the use of second-generation biocompatible fluids is associated with a better preservation of residual kidney function and urine output although these changes might be secondary to a decrease in ultrafiltration capacity. Moreover, no improvements in peritoneal membrane function could be demonstrated using second-generation PD fluids [12][13][14].

In 24 children treated with second-generation PD fluids only, serial peritoneal biopsies showed early fibroblast activation, neoangiogenesis, and vasculopathy. In these children, microvascular density and peritoneal transport rates (D/P creatinine at 2 hours) correlated well [15]. These data demonstrate that biocompatible solutions too lead to early inflammation, epithelial-to-mesenchymal transition, submesothelial thickening, angiogenesis, and vasculopathy in pediatric patients.

The lack of clinical benefits with the use of neutral pH, low GDP solutions and the persistence of histopathological and functional changes of the peritoneal membrane induced using these so-called biocompatible solutions swept aside the biocompatibility hypothesis. An unphysiologically high glucose concentration, a feature common to both first- and second-generation PD fluids, led to the development of the “glucose hypothesis”.

The glucose hypothesis: systemic and peritoneal effects of glucose exposure

During a PD dwell using either first- or second-generation PD fluids, bi-directional transport of solutes across the peritoneal membrane leads to systemic absorption of glucose. Daily systemic glucose absorption is estimated to vary between 90 - 300g [16][17] accounting for a significant caloric load, subsequently increasing fat mass and dyslipidemia. The rise in plasma glucose and GDPs, secondary to the diffusion from the PD fluid to the patient’s circulation, promote the formation of advanced glycosylation end products (AGEs) in plasma and lead to glucose-induced cytotoxic effects [18][19]. Cytotoxicity of glucose is linked to several molecular disturbances. Firstly, AGEs bind to their receptors (RAGE) and induce inflammatory and pro-angiogenic effects through the generation of reactive oxygen species and by the release of cytokines and growth factors. Glucose also triggers intracellular signaling via protein kinase C and polyol pathways and intracellular hyperglycemia causes metabolic disturbances leading to an increase in the ratio of NADH/NAD+, a state known to be induced by insufficient oxygen supply. This glucose-induced pseudohypoxia causes hypoxia-inducible-factor gene expression, subsequently leading to an upregulation of genes encoding for profibrotic and angiogenic factors such as vascular endothelial growth factor (VEGF) and transforming growth factor-beta (TGF-β), contributing to angiogenesis and extracellular matrix deposition [20][21][22]. The cytotoxic effects of glucose thus lead pro-inflammatory, pro-fibrotic and pro-angiogenic changes, which are evident in the peritoneal membrane exposed to the PD fluids [4][15].

New therapeutic approaches

Recent advances in PD fluid developments focused on strategies to counteract the peritoneal and systemic toxicity of glucose-based PD fluids. Hereby, two main strategies have emerged:

(i) The osmotic approach whereby glucose is replaced by an alternative osmotic agent.

(ii) The metabolic approach whereby the PD fluid is supplemented with (an) agent(s) that mitigate the metabolic effects of the glucose exposure.

Before discussing new developments in PD fluids, we first discuss the already commercially available alternatives to glucose-based PD fluids.

In general, it should be acknowledged that residual cytotoxicity through mechanisms unrelated to glucose or glucose degradation products is possible. Buffer-related toxicity has been suggested in studies assessing cytotoxicity of different glucose-based fluids [23]. Also, tonicity or osmolality-related changes to the peritoneal membrane have been described in preclinical studies, unrelated to the high-glucose induced pseudohypoxia[24][25][26]. Identifying these pathways will help to complete the picture of what makes a fluid truly biocompatible.

Commercially available alternatives to glucose-based PD fluids

Icodextrin is a starch-derived high-molecular weight glucose polymer used in peritoneal dialysis as an alternative to glucose. Its larger molecular size causes it to be less readily absorbed than glucose. After entering the circulation, icodextrin is metabolized into smaller oligosaccharides such as maltose, maltotriose and maltotetraose. To date, no histopathological data on the effects of icodextrin use during PD have been published. Clinical studies including randomized controlled trials show improved ultrafiltration with better fluid status control when using icodextrin, especially in patients with fast peritoneal membrane transport status and in those not meeting ultrafiltration goals and at risk of fluid overload [27][28]. Replacement of a glucose dwell by icodextrin showed better insulin sensitivity in non-diabetic patients treated with PD [29]. In patients with diabetes mellitus and treated with PD, a glucose-sparing PD prescription using icodextrin and amino-acid-based PD fluids improved HbA1c results [30]. These data support that lowering glucose exposure during PD lowers the systemic effects of PD-associated glucose absorption. It has to be acknowledged that, to date, the largest body of evidence on the use of non-glucose PD fluids is with icodextrin, with a clear signal of safety and efficacy. Future research into patient-centered outcomes and cost-effectiveness associated with icodextrin is needed.

Amino-acid-based PD fluids are solutions composed of electrolytes, a buffer and a mixture of amino-acids as the osmotic agent. Amino-acid based PD fluids were developed to optimize nutritional status of malnourished patients on PD. Preclinical data on peritoneal membrane cytotoxicity are limited and conflicting, and no histopathological data describing the effects of amino-acid PD fluids on the peritoneal membrane are available to date [8][31]. Clinical relevance in terms of improving nutritional status by the use of long-term amino-acid-based PD fluids is limited as only a short-term (7 days follow-up) small-sized (8 patients) trial was published showing small improvement in protein kinetics [32].

All together, the use of glucose-based PD solutions remains indispensable for a full-dose PD prescription. Despite maximizing icodextrin and amino-acid-based PD fluids use in the PD prescription, patients continue to be exposed to a significant carbohydrate absorption, glucose exposure and GDP absorption [33].

Promising new osmometabolic agents

L-carnitine is an osmotically and metabolically active compound essential for fatty acid metabolism and mitochondrial function with a molecular weight similar to glucose. It is highly water soluble and chemically stable in an aqueous solution and thus suitable for use in PD. Preclinical in vitro and in vivo studies demonstrated improved endothelial cell survival, increased aquaporin-1 expression on endothelial cells, and reduced glucose-induced cytotoxicity when PD-fluids were supplemented with L-carnitine [34][35]. Reassuringly, equimolar solutions of glucose and L-carnitine result in comparable net ultrafiltration with L-carnitine supplemented fluids causing less mesothelial damage and fewer vascular alterations [34][35]. A clinical study randomized 35 non-diabetic patients treated with PD to a PD prescription with glucose-based day dwells versus 0.1% L-carnitine supplemented glucose-based dwells for a treatment period of 4 months. Both groups received icodextrin overnight. Insulin sensitivity improved in the patients who received L-carnitine supplemented PD [36]. Importantly, supplementation with L-carnitine was well tolerated and peritoneal membrane function did not change differently between groups. Patients receiving L-carnitine supplemented PD showed no change in urine output while patients in the control group significantly lost diuresis over the study period. Osmotic diuresis induced by L-carnitine absorption is suggested as the cause of maintained urine output in the intervention group [36].

Xylitol is a 5-carbon sugar used as a sugar substitute in parental nutrition. It is an osmotically active compound with a low glycemic index causing a slower and lower increase in plasma glucose levels and less insulin stimulation compared to when glucose is absorbed. An old-dated clinical trial published in 1982 showed 50% reduction in insulin requirement and improved metabolic parameters when 6 insulin-dependent diabetics received 1.5% and 3.0% xylitol PD dwells compared to when receiving glucose-based PD [37].

Recently, the combined use of 0.7% or 1.5% xylitol with 0.02% L-carnitine and 0.5% glucose has been investigated (Table II.).

Table II.Composition of the novel Xylitol, L-carnitine, glucose based PD fluid

	Plasma reference (adult)	Xylitol – L-carnitine - Glucose
Electrolytes (mmol/L)
Sodium	136-145	132
Calcium	1.12-1.32	1.3
Magnesium	0.65-1.05	0.5
Chloride	98-107	101
Potassium	3.5-5.1	0
Buffer (mmol/L)
Lactate	0.5-2	35
pH	7.4	6.5-7.5
Osmotic agent (g/dL) (osmolality)
Xylitol		0.7/1.5/2.0
L-Carnitine		0.02
Glucose	0.05 - 0.1	0.5/0.5/1.5
Osmolality	280-300	346.5/399.1/480.8

In vitro, a PD fluid containing a low-dose glucose, L-carnitine, and xylitol improved cell viability of human umbilical vein endothelial cells of mothers with or without gestational diabetes, improved human mesothelial cell viability and better preserved mesothelial cell layer integrity compared to glucose-based PD fluids [38][39]. Importantly, the low dose glucose in this PD fluid did not have the deleterious histopathological effects of higher glucose concentrations in first- and second-generation PD fluids [39]. A recently published open-label phase 2 trial compared safety and tolerability of the xylitol – L-carnitine – glucose PD fluid to a conventional glucose and icodextrin PD prescription in 10 CAPD patients over a 4-week period. The use of xylitol - L-carnitine – glucose was well tolerated and patients did not experience infusion pain nor discomfort. Adequacy and peritoneal transport characteristics did not differ between groups [26]. Currently, a phase 3 randomized controlled study with blinded outcome assessment is recruiting in Italy, Denmark, Sweden, UK, Germany and Spain (ELIXIR trial, NCT03994471 [40]). This study aims to randomize 170 CAPD patients to either a standard PD regimen using 1 to 3 glucose-based day dwells and icodextrin overnight versus 1 to 3 day exchanges using 0.7-1.5% xylitol, 0.02% L-carnitine and 0.5% glucose and icodextrin overnight for 6 months. The primary endpoint is non-inferiority in weekly Kt/Vurea. Secondary endpoints include 24h peritoneal ultrafiltration, residual kidney function, urine output, metabolic parameters on lipid and glucose metabolism, patient reported outcome measures, and safety [40]. Data collection is expected to be completed by the end of 2025.

Low glutamine levels in the peritoneal cavity during PD are associated with cytotoxicity related to reduced glutamine-dependent post translational protein modification (so-called O-GlcNAcylation) [41]. Glutamine supplementation of glucose-based PD fluids enables heat-shock-protein mediated cytoprotection. Supplementation of glucose-based PD fluids with the alanine-glutamine dipeptide allows the release of glutamine within the peritoneal cavity. In vitro, in vivo and pilot studies have demonstrated better survival of mesothelial cells, lower endothelial cell damage and better preservation of the peritoneal barrier when glucose-based dialysis fluids were supplemented with the glutamine-releasing alanine-glutamine dipeptide compared to no supplementation [41][42][43][44][45][46][47]. These studies also showed an improved peritoneal membrane immune function, a reduction in oxidative stress and restored stress responses [41][42][43][44][45][46][47]. A phase 2 randomized controlled crossover study in 6 PD patients compared the effects of alanine-glutamine-supplemented PD fluids versus placebo-supplemented PD fluids over a period of 8 weeks. Results showed improved markers of peritoneal membrane integrity, reduced systemic inflammation, and enhanced peritoneal membrane immune competence [48].

Mesothelial cells express both sodium/glucose cotransporter (SGLT) 1 and SGLT2 and therefore it is relevant to assess the effects of SGLT1/2 inhibitors use in PD. Indeed, inhibiting glucose absorption across the peritoneal membrane through inhibiting SGLT1/2-mediated glucose transport might decrease local and systemic glucose-related toxicity while also maintaining osmotic gradient hence enhancing ultrafiltration capacity. In vitro studies showed that empagliflozin and dapagliflozin reduce peritoneal fibrosis and epithelial-to-mesenchymal transition [49][50][51][52]. Animal studies with intraperitoneal administration of dapagliflozin showed improvements in peritoneal membrane integrity and enteric empagliflozin administration reduced glucose uptake and protected against glucose-induced epithelial-to-mesenchymal transition [50][51][53][54]. However, additional data suggest that SGLT1-mediated transport might be more important in facilitating peritoneal glucose transport compared to SGLT2 [55]. The EMPOWERED trial (jRCTs051230081) is a currently recruiting randomized double-blind placebo-controlled crossover trial randomizing 36 Japanese patients with heart failure and treated with PD to two 8-weeks treatment periods of peritoneal dialysis either complemented with oral empagliflozin or placebo. The primary endpoint of the study is the change in the daily ultrafiltration volume from baseline to week 8 [56]. Other randomized controlled trials assessing the effects of SGLT2-inhibitors in patients on peritoneal dialysis are assessing brain natriuretic peptide levels as primary endpoint (jRCT1011210022), glucose absorption from the PD fluid (NCT05671991) or reno- and cardioprotective efficacy and safety (NCT05374291).

2-Deoxyglucose is a synthetic glucose analog that inhibits glycolysis and so counters TGF-β1-mediated profibrotic signaling. In vitro studies showed that supplementation of PD fluid with 2-deoxyglucose improved mesothelial cell survival, reduced epithelial-to-mesenchymal transition, reduced fibrotic changes and improved peritoneal mesothelial and endothelial barrier integrity [57][58]. Clinical validation is pending.

Taurine, hyperbranched polyglycerol, lithium, and steviol glycosides are other molecules under preclinical investigation. All demonstrated peritoneal membrane protection in vitro and in animal models but lack clinical trial data [59][60][61][62].

Of note, adapted PD fluids have been investigated in recent years such as glucose polymers with low polydispersity, bimodal PD combining crystalloid and colloid osmosis, low-sodium and sodium-free PD solutions. While these modifications may lower carbohydrate absorption and increase sodium removal, they do not eliminate glucose exposure, suggesting a potential role for adjunct metabolic protection[63][64][65].

Conclusion

The ideal PD solution should ensure effective solute clearance, ultrafiltration, preserve peritoneal membrane integrity, and limit systemic toxicity. Glucose-based PD fluids, while effective in providing solute and water removal, contribute to peritoneal membrane damage and systemic complications. Amino-acid and icodextrin-based PD fluids offer the potential to reduce glucose exposure and its related local and systemic toxicity; however, they do not eliminate the need for of glucose-based PD fluids. Emerging osmometabolic PD fluids combining xylitol, L-carnitine, and low-dose glucose or PD fluids supplemented with alanine-glutamine show the most promise in better preserving peritoneal membrane integrity and lowering systemic toxicity of the PD fluid based while maintaining adequate solute and water removal compared to glucose-based PD fluids.

Strategies to reduce PD-related glucose toxicity, including metabolic adjuncts and SGLT inhibitors represent an evolving research frontier. Clinicians, researchers and industry must engage in structural collaboration to increase knowledge around PD fluid toxicity, to research existing solutions and to support new developments. Without reliable involvement from any party, opportunities to improve the outcomes of patients treated with peritoneal dialysis will be delayed.

Authors’ Contributions

The authors declare that no generative artificial intelligence tools were used for the writing of this manuscript.

The manuscript was drafted by KF. CS and KF wrote the manuscript. FVH and FJ reviewed the manuscript and provided critical feedback.

All authors approved the final English and French versions of the manuscript submitted to BDD.

Funding

The authors received no funding for the writing of this article.

ORCIDids

Celeste Smeys : https://orcid.org/0000-0003-3924-6764

Freya Van Hulle : https://orcid.org/0000-0001-7079-4705

Florine Janssens : https://orcid.org/0009-0004-2863-6155

Karlien François : https://orcid.org/0000-0003-0071-8402

Conflicts of Interest

The authors declare no conflicts of interest.

References

1. Boenink R.. The ERA Registry Annual Report 2022: Epidemiology of Kidney Replacement Therapy in Europe, with a focus on sex comparisons. Clin Kidney J. 2025; 18(2)
2. Kumar V.A.. Survival of propensity matched incident peritoneal and hemodialysis patients in a United States health care system. Kidney Int. 2014; 86(5):1016-22.
3. Bonenkamp A.A.. Trends in home dialysis use differ among age categories in past two decades: A Dutch registry study. Eur J Clin Invest. 2022; 52(1)
4. Williams J.D.. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002; 13(2):470-479.
5. Davies S.J.. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol. 2001; 12(5):1046-1051.
6. Grossin N.. Improved in vitro biocompatibility of bicarbonate-buffered peritoneal dialysis fluid. Perit Dial Int. 2006; 26(6):664-70.
7. Mortier S.. Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. Kidney Int. 2005; 67(4):1559-65.
8. Mortier S.. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane. Kidney Int. 2004; 66(3):1257-65.
9. Sugiyama N.. Low-GDP, pH-neutral solutions preserve peritoneal endothelial glycocalyx during long-term peritoneal dialysis. Clin Exp Nephrol. 2021; 25(9):1035-1046.
10. Nakao M.. Risk factors for encapsulating peritoneal sclerosis: Analysis of a 36-year experience in a University Hospital. Nephrology (Carlton. 2017; 22(11):907-912.
11. Nakayama M.. Pathophysiology of encapsulating peritoneal sclerosis: lessons from findings of the past three decades in Japan. Clin Exp Nephrol. 2023; 27(9):717-727.
12. Cho Y.. The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients. Kidney Int. 2013; 84(5):969-79.
13. Htay H.. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst Rev. 2018; 10(10)
14. Yohanna S.. Effect of Neutral-pH, Low-Glucose Degradation Product Peritoneal Dialysis Solutions on Residual Renal Function, Urine Volume, and Ultrafiltration: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2015; 10(8):1380-8.
15. Schaefer B.. Neutral pH and low-glucose degradation product dialysis fluids induce major early alterations of the peritoneal membrane in children on peritoneal dialysis. Kidney Int. 2018; 94(2):419-429.
16. Grodstein G.P.. Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int. 1981; 19(4):564-7.
17. Kotla S.K., Saxena A., Saxena R.. A Model To Estimate Glucose Absorption in Peritoneal Dialysis: A Pilot Study. Kidney360. 2020; 1(12):1373-1379.
18. Poole C.Y.. NEPP" peritoneal dialysis regimen has beneficial effects on plasma CEL and 3-DG, but not pentosidine, CML, and MGO. Perit Dial Int. 2012; 32(1):45-54.
19. Zeier M.. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?. Kidney Int. 2003; 63(1):298-305.
20. Krediet R.T.. Physiology of peritoneal dialysis; pathophysiology in long-term patients. Front Physiol. 2024; 15
21. Krediet R.T., Parikova A.. Relative Contributions of Pseudohypoxia and Inflammation to Peritoneal Alterations with Long-Term Peritoneal Dialysis Patients. Clin J Am Soc Nephrol. 2022; 17(8):1259-1266.
22. Krediet R.T., Parikova A.. Glucose-induced pseudohypoxia and advanced glycosylation end products explain peritoneal damage in long-term peritoneal dialysis. Perit Dial Int. 2024; 44(1):6-15.
23. Dioos B.. Biocompatibility of a new PD solution for Japan, Reguneal, measured as in vitro proliferation of fibroblasts. Clin Exp Nephrol. 2018; 22(6):1427-1436.
24. Sun T.. Excessive salt intake increases peritoneal solute transport rate via local tonicity-responsive enhancer binding protein in subtotal nephrectomized mice. Nephrol Dial Transplant. 2019; 34(12):2031-2042.
25. Seeger H.. The potential role of NFAT5 and osmolarity in peritoneal injury. Biomed Res Int. 2015.
26. Kuper C., Beck F.X., Neuhofer W.. NFAT5 contributes to osmolality-induced MCP-1 expression in mesothelial cells. Mediators Inflamm. 2012.
27. Goossen K.. Icodextrin Versus Glucose Solutions for the Once-Daily Long Dwell in Peritoneal Dialysis: An Enriched Systematic Review and Meta-analysis of Randomized Controlled Trials. Am J Kidney Dis. 2020; 75(6):830-846.
28. Lin A.. Randomized controlled trial of icodextrin versus glucose containing peritoneal dialysis fluid. Clin J Am Soc Nephrol. 2009; 4(11):1799-804.
29. Moraes T.P.. Icodextrin reduces insulin resistance in non-diabetic patients undergoing automated peritoneal dialysis: results of a randomized controlled trial (STARCH. Nephrol Dial Transplant. 2015; 30(11):1905-11.
30. Li P.K.. Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients. J Am Soc Nephrol. 2013; 24(11):1889-900.
31. Reimann D.. Amino acid-based peritoneal dialysis solution stimulates mesothelial nitric oxide production. Perit Dial Int. 2004; 24(4):378-84.
32. Tjiong H.L.. Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis. J Am Soc Nephrol. 2005; 16(5):1486-93.
33. Holmes C.J., Shockley T.R.. Strategies to Reduce Glucose Exposure in Peritoneal Dialysis Patients. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. 2000; 20(2_suppl):37-41.
34. Bonomini M.. L-carnitine is an osmotic agent suitable for peritoneal dialysis. Kidney Int. 2011; 80(6):645-54.
35. Gaggiotti E.. Prevention of peritoneal sclerosis: a new proposal to substitute glucose with carnitine dialysis solution (biocompatibility testing in vitro and in rabbits. Int J Artif Organs. 2005; 28(2):177-87.
36. Bonomini M.. Effect of an L-carnitine-containing peritoneal dialysate on insulin sensitivity in patients treated with CAPD: a 4-month, prospective, multicenter randomized trial. Am J Kidney Dis. 2013; 62(5):929-38.
37. Bazzato G.. Xylitol as osmotic agent in CAPD: an alternative to glucose for uremic diabetic patients?. Trans Am Soc Artif Intern Organs. 1982; 28:280-6.
38. Bonomini M.. Effect of peritoneal dialysis fluid containing osmo-metabolic agents on human endothelial cells. Drug Des Devel Ther. 2016; 10:3925-3932.
39. Piccapane F.. A Novel Formulation of Glucose-Sparing Peritoneal Dialysis Solutions with l-Carnitine Improves Biocompatibility on Human Mesothelial Cells. Int J Mol Sci. 2020; 22(1)
40. Bonomini M.. Rationale and design of ELIXIR, a randomized, controlled trial to evaluate efficacy and safety of XyloCore, a glucose-sparing solution for peritoneal dialysis. Perit Dial Int. 2025; 45(1):17-25.
41. Herzog R.. Dynamic O-linked N-acetylglucosamine modification of proteins affects stress responses and survival of mesothelial cells exposed to peritoneal dialysis fluids. J Am Soc Nephrol. 2014; 25(12):2778-88.
42. Bartosova M.. Alanyl-Glutamine Restores Tight Junction Organization after Disruption by a Conventional Peritoneal Dialysis Fluid. Biomolecules. 2020; 10(8)
43. Ferrantelli E.. The dipeptide alanyl-glutamine ameliorates peritoneal fibrosis and attenuates IL-17 dependent pathways during peritoneal dialysis. Kidney Int. 2016; 89(3):625-35.
44. Herzog R.. Peritoneal Dialysis Fluid Supplementation with Alanyl-Glutamine Attenuates Conventional Dialysis Fluid-Mediated Endothelial Cell Injury by Restoring Perturbed Cytoprotective Responses. Biomolecules. 2020; 10(12)
45. Herzog R.. Functional and Transcriptomic Characterization of Peritoneal Immune-Modulation by Addition of Alanyl-Glutamine to Dialysis Fluid. Sci Rep. 2017; 7(1)
46. Kratochwill K.. Addition of Alanyl-Glutamine to Dialysis Fluid Restores Peritoneal Cellular Stress Responses - A First-In-Man Trial. PLoS One. 2016; 11(10)
47. Kratochwill K.. Alanyl-glutamine dipeptide restores the cytoprotective stress proteome of mesothelial cells exposed to peritoneal dialysis fluids. Nephrol Dial Transplant. 2012; 27(3):937-46.
48. Vychytil A.. A randomized controlled trial of alanyl-glutamine supplementation in peritoneal dialysis fluid to assess impact on biomarkers of peritoneal health. Kidney Int. 2018; 94(6):1227-1237.
49. Balzer M.S.. SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate. Biomolecules. 2020; 10(11)
50. Shentu Y.. Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-beta/Smad signaling. Int Immunopharmacol. 2021; 93
51. Shi P.. The antioxidative effects of empagliflozin on high glucose‐induced epithelial-mesenchymal transition in peritoneal mesothelial cells via the Nrf2/HO-1 signaling. Ren Fail. 2022; 44(1):1528-1542.
52. Zhou Y.. SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2. Biomed Pharmacother. 2019; 109:1327-1338.
53. Lho Y.. Empagliflozin attenuates epithelial-to-mesenchymal transition through senescence in peritoneal dialysis. Am J Physiol Renal Physiol. 2nd; 327(3):363-372.
54. Martus G.. SGLT2 inhibition does not reduce glucose absorption during experimental peritoneal dialysis. Perit Dial Int. 2021; 41(4):373-380.
55. Vorobiov M.. Blockade of sodium-glucose co-transporters improves peritoneal ultrafiltration in uraemic rodent models. Perit Dial Int. 2024; 44(1):48-55.
56. Doi Y.. Effects of sodium-glucose co-transporter 2 inhibitors on ultrafiltration in patients with peritoneal dialysis: a protocol for a randomized, double-blind, placebo-controlled, crossover trial (EMPOWERED. Clin Exp Nephrol. 2024; 28(7):629-635.
57. Pitaraki E.. 2-Deoxy-glucose ameliorates the peritoneal mesothelial and endothelial barrier function perturbation occurring due to Peritoneal Dialysis fluids exposure. Biochem Biophys Res Commun. 2024; 693
58. Si M.. Inhibition of hyperglycolysis in mesothelial cells prevents peritoneal fibrosis. Sci Transl Med. 2019; 11(495)
59. Herzog R.. Lithium preserves peritoneal membrane integrity by suppressing mesothelial cell alphaB-crystallin. Sci Transl Med. 2021; 13(608)
60. Kopytina V.. Steviol glycosides as an alternative osmotic agent for peritoneal dialysis fluid. Front Pharmacol. 2022; 13
61. Mendelson A.A.. Hyperbranched polyglycerol is an efficacious and biocompatible novel osmotic agent in a rodent model of peritoneal dialysis. Perit Dial Int. 2013; 33(1):15-27.
62. Nishimura H.. Evaluation of taurine as an osmotic agent for peritoneal dialysis solution. Perit Dial Int. 2009; 29(2):204-16.
63. Freida P.. The contribution of combined crystalloid and colloid osmosis to fluid and sodium management in peritoneal dialysis. Kidney Int Suppl. 2008(108):102-11.
64. Leypoldt J.K.. Low-Polydispersity Glucose Polymers as Osmotic Agents for Peritoneal Dialysis. Perit Dial Int. 2015; 35(4):428-35.
65. Rutkowski B.. Low-Sodium Versus Standard-Sodium Peritoneal Dialysis Solution in Hypertensive Patients: A Randomized Controlled Trial. Am J Kidney Dis. 2016; 67(5):753-61.